BlueWillow Biologics

BlueWillow Biologics is developing and enabling a new generation of safe and effective intranasal vaccines to protect the global population from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax adjuvant platform activates the body's first line of defense—mucosal immunity—while also inducing systemic immunity. We are a clinical-stage company advancing a range of proprietary programs, including peanut allergy, HSV-2, Covid-19, anthrax, pandemic influenza, and RSV.On May 7, 2018, NanoBio Corporation officially changed its name to BlueWillow Biologics and completed Series A financing.